Market Overview:
The global dermatophytosis therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of dermatophytosis, rising awareness about available treatment options, and growing demand for over-the-counter (OTC) drugs. In terms of type, the Rx segment is expected to dominate the global dermatophytosis therapeutics market during the forecast period. This segment is projected to grow at a CAGR of 5.7% from 2018 to 2030. By application, hospital settings are expected to account for the largest share of the global dermatophytosis therapeutics market in 2018. However, clinics are projected to register highest growth rate during the forecast period owing high prevalence rates and increasing adoption rates for advanced therapies such as laser therapy and photodynamic therapy (PDT). Regionally, North America is estimated account for majority share in terms revenue generated by sales of drugs used in treatmentof Dermatomycoses followed by Europe .
Product Definition:
Dermatophytosis Therapeutics is a drug used to treat skin infections caused by fungi. It is important because it can help clear up the infection and prevent it from spreading.
Rx:
Rx is a term used for medication or drug. It is also used in case of any disease, where the body needs to be treated with drugs. In dermatology it means a medicine that helps cure skin diseases like psoriasis, eczema and acne rosacea etc.
It has been observed that the number of people suffering from these diseases has increased over the years and this increase can be attributed to various reasons such as changes in lifestyle, unhealthy diet habits.
OTC:
OTC stands for Over-the-Counter and is a market term used to define products that are sold without prescription. OTC drugs are usually for external use only, but some can be used internally as well. They do not require any medical prescription because they are classified under the category of “nonprescription drug” by U.S federal law. According to the Federal Trade Commission (FTC), over-the-counter (OTC) sales in the U.
Application Insights:
The other application segment accounted for the largest revenue share in 2017 and is anticipated to witness significant growth over the forecast period. The increasing prevalence of atopic dermatitis, contact eczema, and psoriasis among others has led to an increased demand for Dermatophytosis treatment drugs across the globe. In addition, a rise in awareness about these diseases coupled with availability of advanced therapies is expected to propel market growth over the forecast period.
Clinic application was estimated as most prominent segment owing to high product penetration along with rising incidence of chronic skin diseases such as psoriasis and eczema that require regular monitoring & treatment procedures at clinics. Increasing number of patients suffering from chronic skin conditions have necessitated an increase in dermatology clinic appointments which eventually resulted in higher product sales compared with other applications. Moreover, growing emphasis on early diagnosis coupled with increasing patient awareness regarding early detection & diagnosis are further anticipated to boost market growth during future years span (2030 - 2036).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of dermatophytosis and growing awareness about various treatment options. In addition, availability of effective and advanced drugs for treatment of this condition is one major factor responsible for regional growth.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure, and increasing patient awareness regarding available treatments for dermatophytosis. Moreover, rise in number of international tourist destinations including Mount Everest (Nepal) and Kanchenjunga (Sikkim), which are prone to high incidence rate of this disease will boost revenue generation from Dermatology products over the next few years ‰â€˜‘’).
Growth Factors:
- Increasing incidence of dermatophytosis across the globe
- Rising awareness about the treatment and prevention of dermatophytosis
- Growing demand for better and more effective therapeutics for dermatophytosis
- Technological advancements in the field of Dermatophytosis Therapeutics market
- increasing funding and investment for research and development in Dermatophytosis Therapeutics market
Scope Of The Report
Report Attributes
Report Details
Report Title
Dermatophytosis Therapeutics Market Research Report
By Type
Rx, OTC
By Application
Hospital, Clinic, Other
By Companies
Novartis, Pfizer, Sanofi-Aventis, Merck, Enzon Pharmaceuticals, Bayer, Astellas Pharma, GSK, Abbott
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
209
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Dermatophytosis Therapeutics Market Report Segments:
The global Dermatophytosis Therapeutics market is segmented on the basis of:
Types
Rx, OTC
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Sanofi-Aventis
- Merck
- Enzon Pharmaceuticals
- Bayer
- Astellas Pharma
- GSK
- Abbott
Highlights of The Dermatophytosis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Rx
- OTC
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dermatophytosis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dermatophytosis Therapeutics is a clinical stage biotechnology company focused on the development of novel dermatophyte-based therapies for the treatment of skin diseases. The company's lead product candidate, DPT-100, is a novel topical therapy for the treatment of moderate to severe eczema.
Some of the major players in the dermatophytosis therapeutics market are Novartis, Pfizer, Sanofi-Aventis, Merck, Enzon Pharmaceuticals, Bayer, Astellas Pharma, GSK, Abbott.
The dermatophytosis therapeutics market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dermatophytosis Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Dermatophytosis Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Dermatophytosis Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Dermatophytosis Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Dermatophytosis Therapeutics Market Size & Forecast, 2020-2028 4.5.1 Dermatophytosis Therapeutics Market Size and Y-o-Y Growth 4.5.2 Dermatophytosis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Rx
5.2.2 OTC
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dermatophytosis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dermatophytosis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Rx
9.6.2 OTC
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Rx
10.6.2 OTC
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Rx
11.6.2 OTC
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Rx
12.6.2 OTC
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Rx
13.6.2 OTC
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dermatophytosis Therapeutics Market: Competitive Dashboard
14.2 Global Dermatophytosis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Sanofi-Aventis
14.3.4 Merck
14.3.5 Enzon Pharmaceuticals
14.3.6 Bayer
14.3.7 Astellas Pharma
14.3.8 GSK
14.3.9 Abbott